Diurnal Group (DNL) Hits New 1-Year High Following Insider Buying Activity

Shares of Diurnal Group PLC (LON:DNL) reached a new 52-week high during mid-day trading on Monday following insider buying activity. The company traded as high as GBX 173 ($2.35) and last traded at GBX 170 ($2.31), with a volume of 14277 shares traded. The stock had previously closed at GBX 170 ($2.31).

Specifically, insider John Goddard acquired 10,791 shares of the stock in a transaction dated Friday, January 5th. The stock was purchased at an average cost of GBX 540 ($7.32) per share, with a total value of £58,271.40 ($79,022.78). Also, insider Martin Whitaker acquired 3,703 shares of the stock in a transaction dated Monday, November 27th. The stock was acquired at an average cost of GBX 135 ($1.83) per share, with a total value of £4,999.05 ($6,779.29).

Separately, Numis Securities reissued a “buy” rating and issued a GBX 185 ($2.51) price objective on shares of Diurnal Group in a research report on Monday, December 18th.

The firm has a market cap of $115.08 and a PE ratio of -986.11.

WARNING: This report was originally reported by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://baseballnewssource.com/markets/diurnal-group-dnl-hits-new-1-year-high-following-insider-buying-activity/1821719.html.

Diurnal Group Company Profile

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with our FREE daily email newsletter.

 


Latest News

Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees


Leave a Reply

 
© 2006-2018 BBNS.